NBI-98854 50 mg capsule
Phase 1CompletedDevelopment Stage
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
Aug 1, 2013 → Dec 1, 2013
About NBI-98854 50 mg capsule
NBI-98854 50 mg capsule is a phase 1 stage product being developed by Neurocrine Biosciences for Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT01916993. Target conditions include Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects.
What happened to similar drugs?
3 of 4 similar drugs in Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01916993 | Phase 1 | Completed |
Competing Products
20 competing products in Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects